Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsPayablesPrepaid AssetsRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kairos Pharma (KAPA) Accounts Payables (2024 - 2025)

Kairos Pharma's Accounts Payables history spans 2 years, with the latest figure at $199000.0 for Q4 2025.

  • For Q4 2025, Accounts Payables fell 79.94% year-over-year to $199000.0; the TTM value through Dec 2025 reached $199000.0, down 79.94%, while the annual FY2025 figure was $199000.0, 79.94% down from the prior year.
  • Accounts Payables reached $199000.0 in Q4 2025 per KAPA's latest filing, down from $676000.0 in the prior quarter.
  • In the past five years, Accounts Payables ranged from a high of $1.5 million in Q3 2024 to a low of $199000.0 in Q4 2025.